Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and Francisella tularensis Infection

moxifloxacin has been researched along with Francisella tularensis Infection in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Clemens, DL; Dillon, BJ; Horwitz, MA; Lee, BY; Li, Z; Plamthottam, S; Tullius, MV; Wang, R; Yu, CJ; Zink, JI1
Cao, J; Hai, R; Li, H; Peng, Y; Qiao, FY; Wang, YH; Xia, LX1
Clemens, DL; Dillon, BJ; Horwitz, MA; Lee, BY; Li, Z; Zink, JI1
Clemens, DL; Dillon, BJ; Horwitz, MA; Hwang, AA; Lee, BY; Li, Z; Zink, JI1
Careño, E; Herreras, JM; Portero, A; Real, LA; Villarón, S1
Brooks, TJ; Lever, MS; Piercy, T; Steward, J1
Brooks, TJ; Lever, MS; Piercy, T; Simpson, AJ; Steward, J1

Other Studies

7 other study(ies) available for moxifloxacin and Francisella tularensis Infection

ArticleYear
Nanoparticle Formulation of Moxifloxacin and Intramuscular Route of Delivery Improve Antibiotic Pharmacokinetics and Treatment of Pneumonic Tularemia in a Mouse Model.
    ACS infectious diseases, 2019, 02-08, Volume: 5, Issue:2

    Topics: Administration, Intravenous; Animals; Anti-Bacterial Agents; Disease Models, Animal; Female; Francisella tularensis; Injections, Intramuscular; Mice; Mice, Inbred BALB C; Moxifloxacin; Nanoparticles; Pneumonia, Bacterial; Tularemia

2019
A case of Francisella tularensis subspecies holarctica in China.
    Ticks and tick-borne diseases, 2015, Volume: 6, Issue:6

    Topics: Adult; Anti-Bacterial Agents; China; Fluoroquinolones; Francisella tularensis; Humans; Male; Minocycline; Moxifloxacin; Tularemia

2015
Mesoporous Silica Nanoparticles with pH-Sensitive Nanovalves for Delivery of Moxifloxacin Provide Improved Treatment of Lethal Pneumonic Tularemia.
    ACS nano, 2015, Nov-24, Volume: 9, Issue:11

    Topics: Animals; Benzimidazoles; Drug Delivery Systems; Fluoroquinolones; Francisella tularensis; Humans; Hydrogen-Ion Concentration; Macrophages; Mice; Microbial Viability; Moxifloxacin; Nanoparticles; Phosphorous Acids; Pneumonia; Porosity; Silicon Dioxide; Treatment Outcome; Tularemia

2015
Redox-Triggered Release of Moxifloxacin from Mesoporous Silica Nanoparticles Functionalized with Disulfide Snap-Tops Enhances Efficacy Against Pneumonic Tularemia in Mice.
    Small (Weinheim an der Bergstrasse, Germany), 2016, Volume: 12, Issue:27

    Topics: Animals; Drug Delivery Systems; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Nanoparticles; Silicon Dioxide; Tularemia

2016
Infectious nontuberculous serpiginous choroiditis.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2012, Volume: 130, Issue:9

    Topics: Adult; Anti-Infective Agents; Antibodies, Bacterial; Aza Compounds; Bartonella henselae; Cat-Scratch Disease; Choroiditis; Ciprofloxacin; Eye Infections, Bacterial; Fluorescein Angiography; Fluoroquinolones; Francisella tularensis; Humans; Immunoglobulin G; Male; Middle Aged; Moxifloxacin; Quinolines; Tularemia; Vision Disorders; Visual Acuity

2012
In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
    The Journal of antimicrobial chemotherapy, 2005, Volume: 56, Issue:6

    Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Dexamethasone; Disease Models, Animal; Female; Fluoroquinolones; Francisella tularensis; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines; Survival Analysis; Tularemia

2005
Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
    International journal of antimicrobial agents, 2006, Volume: 27, Issue:5

    Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Tularemia

2006